Announcements Trials

Browse Landscape

Phase

Status

Active not recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Carcinoma, Non-Small-Cell Lung 27 Carcinoma, Hepatocellular 26 Small Cell Lung Carcinoma 17 Lung Neoplasms 15 Neoplasms 13 Breast Neoplasms 8 Colorectal Neoplasms 7 Carcinoma, Renal Cell 7 Squamous Cell Carcinoma of Head and Neck 6 Melanoma 6 Uterine Cervical Neoplasms 5 Urinary Bladder Neoplasms 5 Triple Negative Breast Neoplasms 5 Neoplasm Metastasis 5 Carcinoma, Transitional Cell 5 Prostatic Neoplasms 4 Glioblastoma 4 Stomach Neoplasms 3 Solid Tumors 3 Sarcoma, Alveolar Soft Part 3 Sarcoma 3 Liver Neoplasms 3 Extensive Stage Lung Small Cell Carcinoma 3 Carcinoma 3 Treatment-Refractory Solid Tumors 2 Small Cell Lung Cancer Extensive Stage 2 Pancreatic Neoplasms 2 Ovarian Neoplasms 2 Osteosarcoma 2 Nasopharyngeal Carcinoma 2

Interventions

trifluridine tipiracil drug combination 1 reolysin 1 atezolizumab 1 Gemcitabine 1 Albumin-Bound Paclitaxel 1 130-nm albumin-bound paclitaxel 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Anal Cancer Metastatic × atezolizumab × 90 days × Clear all

NCT07280377 2026-05-19

GOBLET

Oncolytics Biotech

Phase 1/2 Active not recruiting

Gastrointestinal

Anal Cancer Metastatic

Data powered by HemOnc (CC BY 4.0) Colophon ⚡